Simple Partial Seizure — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for simple partial seizure. 113 active patents protecting 4 drugs from 4+ originators. First major cliff: 2028. Daily refresh.

4
Approved drugs
113
Active US patents
60/100
Avg vulnerability
—
Annual revenue covered

Originators in Simple Partial Seizure

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Janssen 70 patents Generic (originally UCB Pharma) 28 patents GSK 8 patents Novartis AG (originally Geigy) 7 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating simple partial seizure. Each bar = one year. Y-axis scaled to peak year (42 patents).

42
27
8
28
9
29
8
31
26
33
12
34
8
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Topamax
topiramate
 Janssen 70 66 — 2027-11-16
Keppra
levetiracetam
 Generic (originally UCB Pharma) 28 56 — 2027-09-03
Lamictal
lamotrigine
 GSK 8 64 — 2029-01-07
Tegretol
carbamazepine
 Novartis AG (originally Geigy) 7 55 — 2028-11-10

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8663683 Topamax method of use 80 2027-11-16
8889191 Topamax method of use 80 2027-11-16
8877248 Topamax method of use 80 2027-11-16
8877248 Topamax method of use 80 2027-11-16
8663683 Topamax method of use 80 2027-11-16
8889191 Topamax method of use 80 2027-11-16
8663683 Topamax method of use 80 2027-11-16
8298580 Topamax method of use 80 2027-11-16
8298580 Topamax method of use 80 2027-11-16
8298580 Topamax method of use 80 2027-11-16

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11160786 Keppra formulation 42 2034-03-14
11160786 Keppra formulation 42 2034-03-14
11160786 Keppra formulation 42 2034-03-14
11160786 Keppra formulation 42 2034-03-14
9101545 Topamax formulation 42 2033-03-19
9555005 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9555005 Topamax formulation 42 2033-03-19

Related